[1] BORGHI C, DOMIENIK-KAROWICZ J, TYKARSKI A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update[J]. Cardiology Journal, 2021, 28(1):1-14.
[2] VARELDZIS R, PEREZ A, REISIN E. Hyperuricemia: An intriguing connection to metabolic syndrome, diabetes, kidney disease, and hypertension[J]. Current Hypertension Reports, 2024, 26(6):237-245.
[3] 中国民族卫生协会重症代谢疾病分会, 高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识(2023年版)[J]. 中国实用内科杂志, 2023, 43(6):461-480.
Severe Metabolic Disease Branch of China National Health Association,Multidisciplinary consensus expert group on the diagnosis and treatment of hyperuricemia-related diseases. China multi-disciplinary expert consensus on diagnosis and treatment of hyperuricemia and related diseases(2023 edition) [J]. Chinese Journal of Practical Internal Medicine, 2023, 43(6):461-480.
[4] GUO X L, GAO Y Y, YANG Y X, et al. Amelioration effects of α-viniferin on hyperuricemia and hyperuricemia-induced kidney injury in mice[J]. Phytomedicine, 2023, 116:154868.
[5] MEHMOOD A, ZHAO L, WANG C T, et al. Management of hyperuricemia through dietary polyphenols as a natural medicament: A comprehensive review[J]. Critical Reviews in Food Science and Nutrition, 2019, 59(9):1433-1455.
[6] ISHIKAWA T, MAEDA T, HASHIMOTO T, et al. Long-term safety and effectiveness of the xanthine oxidoreductase inhibitor, topiroxostat in Japanese hyperuricemic patients with or without gout: A 54-week open-label, multicenter, post-marketing observational study[J]. Clinical Drug Investigation, 2020, 40(9):847-859.
[7] 张红忠, 雷林, 罗正江, 等. 初探藤茶的文献研究[J]. 贵州农机化, 2018(3):53-55, 61.
ZHANG H Z, LEI L, LUO Z J, et al. An Initial Exploration of Literature on Ampelopsis Grossedentat[J]. Guizhou Agricultural Mechaniation, 2018(3):53-55, 61.
[8] 李佳川, 李思颖, 王优, 等. 藤茶化学成分、药理作用及质量标志物(Q-marker)预测分析[J]. 西南民族大学学报(自然科学版), 2021, 47(3):254-266.
LI J C, LI S Y, WANG Y, et al. Predictive analysis on chemical composition, pharmacological effects and quality marker (Q-marker) of Ampelopsis grossedentata[J]. Journal of Southwest Minzu University (Natural Science Edition), 2021, 47(3):254-266.
[9] 赵春草, 曾佳. 藤茶的药理作用和安全性研究新进展[J]. 中国药房, 2023, 34(3):380-384.
ZHAO C C, ZENG J. Recent advances on pharmacological effect and safety of Ampelopsis grossedentata[J]. China Pharmacy, 2023, 34(3):380-384.
[10] KOU X J, CHEN N. Pharmacological potential of ampelopsin in Rattan tea[J]. Food Science and Human Wellness, 2012, 1(1):14-18.
[11] 马二秀, 李思颖, 程雪瑶, 等. 藤茶总黄酮抗高尿酸血症及肾功能保护作用研究[J]. 中药药理与临床, 2021, 37(3):80-85.
MA E X, LI S Y, CHENG X Y, et al. Protective effect of total flavonoids from Ampelopsis grossedentata on renal function and anti-hyperuricemia effect[J]. Pharmacology and Clinics of Chinese Materia Medica, 2021, 37(3):80-85.
[12] FENG S M, WU S J, XIE F, et al. Natural compounds lower uric acid levels and hyperuricemia: Molecular mechanisms and prospective[J]. Trends in Food Science & Technology, 2022, 123:87-102.
[13] GALBUSERA C, ORTH P, FEDIDA D, et al. Superoxide radical production by allopurinol and xanthine oxidase[J]. Biochemical Pharmacology, 2006, 71(12):1747-1752.
[14] YU D H, DU J N, HE P, et al. Identification of natural xanthine oxidase inhibitors: Virtual screening, anti-xanthine oxidase activity, and interaction mechanism[J]. International Journal of Biological Macromolecules, 2024, 259:129286.
[15] RAGAB G, ELSHAHALY M, BARDIN T. Gout: An old disease in new perspective-A review[J]. Journal of Advanced Research, 2017, 8(5):495-511.
[16] LIPKOWITZ M S. Regulation of uric acid excretion by the kidney[J]. Current Rheumatology Reports, 2012, 14(2):179-188.
[17] ERALY S A, VALLON V, RIEG T, et al. Multiple organic anion transporters contribute to net renal excretion of uric acid[J]. Physiological Genomics, 2008, 33(2):180-192.
[18] NIGAM S K, BHATNAGAR V. The systems biology of uric acid transporters: The role of remote sensing and signaling[J]. Current Opinion in Nephrology and Hypertension, 2018, 27(4):305-313.
[19] YANG B D, XIN M L, LIANG S F, et al. New insight into the management of renal excretion and hyperuricemia: Potential therapeutic strategies with natural bioactive compounds[J]. Frontiers in Pharmacology, 2022, 13:1026246.
[20] TSUSHIMA Y, NISHIZAWA H, TOCHINO Y, et al. Uric acid secretion from adipose tissue and its increase in obesity[J]. Journal of Biological Chemistry, 2013, 288(38):27138-27149.
[21] BALDWIN W, MCRAE S, MAREK G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome[J]. Diabetes, 2011, 60(4):1258-1269.
[22] NI Q, LU X M, CHEN C C, et al. Risk factors for the development of hyperuricemia: A STROBE-compliant cross-sectional and longitudinal study[J]. Medicine, 2019, 98(42): e17597.
[23] BEN SALEM C, SLIM R, FATHALLAH N, et al. Drug-induced hyperuricaemia and gout[J]. Rheumatology, 2017, 56(5):679-688.
[24] JENKINS C, HWANG J H, KOPP J B, et al. Review of urate-lowering therapeutics: From the past to the future[J]. Frontiers in Pharmacology, 2022, 13:925219.
[25] ZHANG X, WAN D P, YANG G S, et al. Febuxostat is superior to allopurinol in delaying the progression of renal impairment in patients with chronic kidney disease and hyperuricemia[J]. International Urology and Nephrology, 2019, 51(12):2273-2283.
[26] HOSOYA T, SASAKI T, OHASHI T. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: A randomized, double-blinded, controlled phase 2b study[J]. Clinical Rheumatology, 2017, 36(3):649-656.
[27] HOSOYA T, SASAKI T, HASHIMOTO H, et al. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: An exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study[J]. Journal of Clinical Pharmacy and Therapeutics, 2016, 41(3):298-305.
[28] HOSOYA T, OGAWA Y, HASHIMOTO H, et al. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: A phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study[J]. Journal of Clinical Pharmacy and Therapeutics, 2016, 41(3):290-297.
[29] KURIYAMA S. Dotinurad: A novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia[J]. Clinical and Experimental Nephrology, 2020, 24(Suppl 1):1-5.
[30] FITZGERALD J D, DALBETH N, MIKULS T, et al. 2020 American college of rheumatology guideline for the management of gout[J]. Arthritis & Rheumatology, 2020, 72(6):879-895.
[31] 杨冰慧, 李兵, 马金龙, 等. 药用植物藤茶的研究进展[J]. 大连民族大学学报, 2023, 25(3):199-203.
YANG B H, LI B, MA J L, et al. Research progress of medicinal plant vine tea[J]. Journal of Dalian Minzu University, 2023, 25(3):199-203.
[32] ZHOU Q X, ZHOU Q, ZHANG P, et al. Integrating multi-level interactive network and in vivo/vitro studies to explore the protective mechanism of Ampelopsis grossedentata in hyperuricemia[J]. Fitoterapia, 2024, 172:105718.
[33] 孙冰, 赵彦巧, 冯子瑞, 等. 分子对接技术在食品领域的研究进展[J]. 粮食与油脂, 2023, 36(12):17-21.
SUN B, ZHAO Y Q, FENG Z R, et al. Research progress of molecular docking technology in food field[J]. Cereals & Oils, 2023, 36(12):17-21.
[34] 李佳川, 李思颖. 基于分子对接技术的藤茶总黄酮对高尿酸血症肾功能损伤保护机制研究[J]. 中草药, 2021, 52(3):727-735.
LI J C, LI S Y. Protective effect and mechanism of total flavonoids from Ampelopsis grossedentata on renal function injury of hyperuricemia based on molecular docking technology[J]. Acupuncture Research, 2021, 52(3):727-735.
[35] 任凌志, 李思颖, 宋琴, 等. 基于分子对接技术的结果研究藤茶总黄酮抗痛风性关节炎的作用机制[J]. 中药药理与临床, 2022, 38(3):96-101.
REN L Z, LI S Y, SONG Q, et al. Mechanism of total flavonoids from Ampelopsis grossedentata against gouty arthritis based on molecular docking technology[J]. Pharmacology and Clinics of Chinese Materia Medica, 2022, 38(3):96-101.
[36] HOU C L, LIU D, WANG M, et al. Novel xanthine oxidase-based cell model using HK-2 cell for screening antihyperuricemic functional compounds[J]. Free Radical Biology and Medicine, 2019, 136:135-145.
[37] 王元. 藤茶提取物抗高尿酸血症及肾功能保护作用机制研究[D]. 成都: 西南民族大学, 2020.
WANG Y. Study on the mechanism of anti-hyperuricemia and renal function protection of vine tea extract. Chengdu: Southwest University for Nationalities, 2020.
[38] 吴淑慧, 於洪建, 於天, 等. 藤茶提取物的降尿酸作用研究[J]. 食品工业科技, 2021, 42(18):350-355.
WU S H, YU H J, YU T, et al. Study on anti-hyperuricemia effect of Ampelopsis grossedentata extracts[J]. Science and Technology of Food Industry, 2021, 42(18):350-355.
[39] SHIMIZU Y, SAKURADA T, MATSUOKA S, et al. Vine tea (Ampelopsis grossedentata) extract suppresses postprandial uric acid levels via both inhibition of xanthine oxidase and facilitation of uric acid excretion[J]. Current Developments in Nutrition, 2020, 4: nzaa045_107.
[40] ZHANG Z X, MO R M, LIU D B, et al. Research on the efficacy of ganpu vine tea in inhibiting uric acid production[J]. Metabolites, 2023, 13(6):704.
[41] LI X L, LI B Y, MENG X Y, et al. Integrating network pharmacology and experimental validation to reveal the mechanism of vine grape tea polyphenols on hyperuricemia-induced renal injury in mice[J]. Journal of Medicinal Food, 2024, 27(4):312-329.
[42] 李广枝, 卢忠英, 徐敬友, 等. 藤茶二氢杨梅素对小鼠高尿酸血症模型的降尿酸作用[J]. 山地农业生物学报, 2014, 33(4):40-42.
LI G Z, LU Z Y, XU J Y, et al. Effect of dihydromyricetin from Ampelopsis grossedentata on reducing serum uric acid in hyperuricemia model mice[J]. Journal of Mountain Agriculture and Biology, 2014, 33(4):40-42.
[43] ADACHI S I, NIHEI K I, ISHIHARA Y, et al. Anti-hyperuricemic effect of taxifolin in cultured hepatocytes and model mice[J]. Cytotechnology, 2017, 69(2):329-336.
[44] ADACHI S I, KONDO S, SATO Y, et al. Anti-hyperuricemic effect of isorhamnetin in cultured hepatocytes and model mice: Structure-activity relationships of methylquercetins as inhibitors of uric acid production[J]. Cytotechnology, 2019, 71(1):181-192.
[45] TUNG Y T, LIN L C, LIU Y L, et al. Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice[J]. BMC Complementary and Alternative Medicine, 2015, 15:423.
[46] 陈海青, 周璇, 王秀秀. 槲皮素治疗高尿酸血症的机制研究[J]. 光明中医, 2019, 34(9):1340-1344.
CHEN H Q, ZHOU X, WANG X X. Mechanistic study of quercetin in the treatment of hyperuricemia [J]. Guangming Journal of Chinese Medicine, 2019, 34(9):1340-1344.
[47] WANG F Q, ZHAO X, SU X, et al. Isorhamnetin, the xanthine oxidase inhibitor from Sophora japonica, ameliorates uric acid levels and renal function in hyperuricemic mice[J]. Food & Function, 2021, 12(24):12503-12512.
[48] LI Y M, ZHAO Z A, LUO J, et al. Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway[J]. Phytomedicine, 2021, 87:153585.
[49] LIU T Y, GAO H M, ZHANG Y Y, et al. Apigenin ameliorates hyperuricemia and renal injury through regulation of uric acid metabolism and JAK2/STAT3 signaling pathway[J]. Pharmaceuticals, 2022, 15(11):1442.
[50] 严采馨, 田锦鸿, 李璐, 等. 木犀草素通过抑制URAT1与调节Nrf2/HO-1通路改善尿酸诱导的肾脏损伤[J]. 生命科学研究, 2022, 26(2):103-110.
YAN C X, TIAN J H, LI L, et al. Luteolin alleviates hyperuricemic nephropathy by inhibiting URAT1 and regulating Nrf2/HO-1 pathway[J]. Life Science Research, 2022, 26(2):103-110.
[51] 余惠凡, 黄林生, 韩俊祥, 等. 木犀草素对高尿酸血症小鼠降尿酸作用及其机制研究[J]. 时珍国医国药, 2021, 32(5):1071-1074.
YU H F, HUANG L S, HAN J X, et al. Luteolin on uric acid-lowering in hyperuricemia mice and its mechanism [J]. Lishizhen Medicine and Materia Medica Research, 2021, 32(5):1071-1074.
[52] YANG B D, XIN M L, LIANG S F, et al. Naringenin ameliorates hyperuricemia by regulating renal uric acid excretion via the PI3K/AKT signaling pathway and renal inflammation through the NF-κB signaling pathway[J]. Journal of Agricultural and Food Chemistry, 2023, 71(3):1434-1446.
[53] AN M F, SHEN C, ZHANG S S, et al. Anti-hyperuricemia effect of hesperetin is mediated by inhibiting the activity of xanthine oxidase and promoting excretion of uric acid[J]. Frontiers in Pharmacology, 2023, 14:1128699.
[54] DE OLIVEIRA E P, BURINI R C. High plasma uric acid concentration: Causes and consequences[J]. Diabetology & Metabolic Syndrome, 2012, 4:12.
[55] WANG J, CHEN Y, ZHONG H, et al. The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies[J]. Critical Reviews in Food Science and Nutrition, 2022, 62(14):3979-3989.
[56] PAN L B, HAN P, MA S R, et al. Abnormal metabolism of gut microbiota reveals the possible molecular mechanism of nephropathy induced by hyperuricemia[J]. Acta Pharmaceutica Sinica B, 2020, 10(2):249-261.
[57] YIN H, LIU N, CHEN J. The role of the intestine in the development of hyperuricemia[J]. Frontiers in Immunology, 2022, 13:845684.
[58] MENG W Y, CHEN L L, OUYANG K H, et al. Chimonanthus nitens Oliv. leaves flavonoids alleviate hyperuricemia by regulating uric acid metabolism and intestinal homeostasis in mice[J]. Food Science and Human Wellness, 2023, 12(6):2440-2450.
[59] CHEN N, WANG R, LI H, et al. Flavonoid extract of saffron by-product alleviates hyperuricemia via inhibiting xanthine oxidase and modulating gut microbiota[J]. Phytotherapy Research, 2022, 36(12):4604-4619.
[60] WU D, CHEN R H, LI Q H, et al. Tea (Camellia sinensis) ameliorates hyperuricemia via uric acid metabolic pathways and gut microbiota[J]. Nutrients, 2022, 14(13):2666.
[61] YU W, XIE D, YAMAMOTO T, et al. Mechanistic insights of soluble uric acid-induced insulin resistance: Insulin signaling and beyond[J]. Reviews in Endocrine & Metabolic Disorders, 2023, 24(2):327-343.
[62] CHEN L Y, TIAN G W, TANG W D, et al. Protective effect of luteolin on streptozotocin-induced diabetic renal damage in mice via the regulation of RIP140/NF-кB pathway and insulin signalling pathway[J]. Journal of Functional Foods, 2016, 22:93-100.
[63] 童庆. 二氢杨梅素通过调节肠道菌群结构防治肥胖及胰岛素抵抗的作用机制研究[D]. 武汉: 华中科技大学, 2018.
TONG Q. Dihydromyricetin improves obesity and insulin resistance by modulating the composition of gut microbiota. Wuhan: Huazhong University of Science and Technology, 2018.
